BENCHMARK ANIMAL HEALTH LIMITED

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  -41.9%

  £24,020,194 → £13,956,891

• Cash

  +101%

  £237,647 → £477,618

• Net assets

  -27.5%

  -£74,424,336 → -£94,877,316

• Employees

  -39.5%

  43 → 26

• Operating profit

  -118.4%

  -£9,455,166 → -£20,654,065

• Profit before tax

  -102.6%

  -£10,347,275 → -£20,958,493

• Wages

  -56.1%

  £5,167,179 → £2,267,790

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. BENCHMARK ANIMAL HEALTH LIMITED 2014-02-19 → present
2. ENDEAVOUR 142 LIMITED 2014-01-31 → 2014-02-19

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors' have reviewed the Group's forecast for a period of at least 12 months from the date of approval of the financial statements and concluded that the Company should be able to continue to operate as a going concern. Further details are provided in note 2 to the financial statements.”

Group structure

1. BENCHMARK ANIMAL HEALTH LIMITED · parent
   1. Benchmark Animal Health US, Inc 100% · US · Supply of health products
   2. Benchmark Animal Health Inc 100% · Canada · Supply of health products
   3. Benchmark R&D (Thailand) Limited 100% · Thailand · Veterinary services
   4. Benchmark Animal Health Chile SpA 100% · Chile · Supply of health products

Significant events

• “The Health division underwent a significant restructuring in FY24 to create a sustainable and profitable business, concentrating on the core sea lice solution, Salmosan® Vet, while maintaining the capability to deploy Ectosan® Vet and CleanTreat® in the future.”
• “Transitioned CleanTreat® from the PSV model to a future customer-owned infrastructure model, reducing fixed costs and capital exposure.”
• “Successfully demobilised both CleanTreat® PSVs in Q2 and Q3, leading to significant cost savings.”
• “capitalised development costs relating to Ectosan® Vet/CleanTreat® of £13.3m were impaired to nil.”
• “On 25 November, an agreement was signed for the Group to sell the whole Genetics business for consideration of up to £260m, with £230m received up front and up to £30m earnout receivable in three years. Completion of the deal took place on 31 March 2025”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.